ALNY In Top Form, LENS Catches Investors’ Eyes, PRQR, AXON Inch Closer To D-Day

The following are some of the biotech stocks that made their way onto the Day’s Gainers & Losers’ list of September 20, 2017.


1. Alnylam Pharmaceuticals Inc. (ALNY)

Gained 51.71% to close Wednesday’s (Sep.20) trading at $113.84.

News: The Company’s phase III study of Patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, dubbed APOLLO, met its primary efficacy endpoint and all secondary endpoints.

Alnylam expects to file its first New Drug Application in late 2017 and first Marketing Authorisation Application shortly thereafter.

Alnylam ‘s partner Sanofi Genzyme is currently preparing for regulatory filings for Patisiran in Japan, Brazil and other countries, to begin in the first half of 2018. If approved, Alnylam will commercialize Patisiran in the U.S., Canada and Western Europe, with Sanofi Genzyme commercializing the product in the rest of the world.

2. Presbia PLC (LENS)

Gained 22.70% to close Wednesday’s trading at $4.00.

News: No news


The Company’s lead product candidate is Presbia Flexivue Microlens, a revolutionary optical lens implant for treating presbyopia, the age-related loss of near vision.

Near-term catalyst:

The Company expects to seek approval of Presbia Flexivue Microlens in the fourth quarter of this year.

3. Arbutus Biopharma Corporation (ABUS)

Gained 20.72% to close Wednesday’s trading at $6.70.

News: The Company’s lipid nanoparticle (LNP) licensee Alnylam Pharma announced positive data from APOLLO trial.

Patisiran is enabled by Arbutus’ lipid nanoparticle (LNP) technology. Per the terms of the LNP license agreement for Patisiran, Arbutus will be owed single digit royalties on sales of Patisiran.

To know more about ABUS, please visit our Company Spotlight column.

4. Dicerna Pharmaceuticals Inc. (DRNA)

Gained 18.21% to close Wednesday’s trading at $4.48.

News: No news

Near-term catalysts:

— The Company plans to file a clinical trial application (CTA) in Europe for DCR-PHXC for primary hyperoxaluria in late 2017 and commence human clinical trials in the first quarter of 2018.
— File an IND application in the U.S. and/or CTA in Europe for a second candidate for an undisclosed rare disease involving the liver in the second quarter of 2018.
— File an IND application in the U.S. or CTA in Europe for DCR-HBVS program, which targets HBV directly, at approximately the end of 2018.


Gained 11.93% to close Wednesday’s trading at $2.44.

News: No…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *